Looking at life through the prism of psychology, philosophy, mental health and more. Originally created by counsellor, psychotherapist and philosopher Dr Greg Mulhauser, this blog is now the work of an international team of contributors.
Timothy Wilens, an associate professor of psychiatry at Harvard Medical School, says most doctors who prescribe ADHD drugs are already aware that they can trigger psychosis, a rare side effect. Now an advisory panel will discuss whether the Food and Drug Administration should ask makers of attention deficit/hyperactivity disorder drugs to add labelling information about the possible risk of psychosis or mania, especially in children.
Held captive for 54 days by the man she loved, a man later diagnosed with schizophrenia, she still empathized with him and tried to save him. Singer/composer Kathryn Keats shares her story here, with the first excerpt from her forthcoming book called ‘The Ascension’.
Following elderly individuals with depression for periods of up to two years, a University of Pittsburgh trial found that individuals were less likely to have recurrent depression if they received two years of maintenance therapy with the anti-depressant paroxetine. So-called ‘maintenance psychotherapy’ offered once a month for 45 minutes did not prevent recurrent depression.
One in three teens will experience an abusive relationship, but many cases go unreported. And abusive relationships may not always be recognized by teens for what they are, some experts say.
Following successful clinical trials at the University of Bonn on transcranial magnetic stimulation as a treatment for depression, Yale University researchers are now recruiting schizophrenic patients nationally for a clinical trial involving the use of TMS as a treatment for auditory hallucinations.
If we only have a dollar in our pocket, then most of our decisions become financial decisions. If our partner is an abuser or controller, then the majority of our decisions are based on our perception of the abuser’s potential reaction. This is just one aspect of Stockholm Syndrome, as described by our guest contributor, clinical psychologist Dr. Joseph M. Carver.
Federal regulators in the US have approved the world’s first antidepressant skin patch, the selegiline transdermal patch, to be marketed under the name ‘Emsam’. The drug, first approved in the 1980s to help treat Parkinson’s disease, belongs to a category of less frequently used antidepressants prone to interactions with a substance called tyramine. The antidepressant patch will carry a ‘black box’ warning from the FDA.
